Statin combination therapy and cardiovascular risk reduction

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Besseling J, van Capelleveen J, Kastelein JJ, Hovingh GK. LDL cholesterol goals in high-risk patients: how low do we go and how do we get there? Drugs 73(4), 293–301 (2013).
  Medline CASGoogle Scholar
• 2 Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
  Medline CASGoogle Scholar
• 3 Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670–1681 (2010). •• Meta-analysis of 26 randomized controlled statin trials, including intensive treatment, showing the relationship between magnitude of LDL-lowering and reduction of cardiovascular (CV) events.
  Medline CASGoogle Scholar
• 4 Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841), 581–590 (2012). • Meta-analysis of 27 randomized, controlled statin trials showing the relationship between LDL-C lowering and reduction of CV events in patients with lower cardiovascular disease (CVD) risk.
  Medline CASGoogle Scholar
• 5 Chiang CW, Santos RD, Waters DD et al. Reaching C-reactive protein and low-density lipoprotein cholesterol goals in dyslipidemic patients (from the Lipid Treatment Assessment Project [L-TAP] 2). Am. J. Cardiol. 107(11), 1639–1643 (2011).
  MedlineGoogle Scholar
• 6 Foody JM, Sajjan SG, Hu XH et al. Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients. J. Clin. Lipidol. 4(2), 126–132 (2010).
  MedlineGoogle Scholar
• 7 Jukema JW, Chiang CW, Ferrieres J et al. Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2. Curr. Med Res. Opin. 26(11), 2589–2597 (2010).
  Medline CASGoogle Scholar
• 8 Nichols GA, Nag S, Chan W. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am. Heart J. 154(3), 554–560 (2007).
  MedlineGoogle Scholar
• 9 Rodriguez F, Santos RD, Messig M et al. comparison of lipid profiles and attainment of lipid goals in patients <65 years versus patients >/=65 years (from the Lipid Treatment Assessment Project [L-TAP] 2). Am. J. Cardiol. 109(12), 1738–1742 (2012).
  Medline CASGoogle Scholar
• 10 Rublee DA, Burke JP. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Postgrad. Med 122(2), 16–24 (2010).
  MedlineGoogle Scholar
• 11 Santos RD, Waters DD, Tarasenko L et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. Atherosclerosis 224(1), 150–153 (2012).
  Medline CASGoogle Scholar
• 12 Waters DD, Brotons C, Chiang CW et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 120(1), 28–34 (2009).
  Medline CASGoogle Scholar
• 13 Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis. Atherosclerosis 241(2), 450–454 (2015).
  Medline CASGoogle Scholar
• 14 Anderson TJ, Gregoire J, Hegele RA et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 29(2), 151–167 (2013).
  MedlineGoogle Scholar
• 15 Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(1), 3–46 (2011).
  Medline CASGoogle Scholar
• 16 Jellinger PS, Smith DA, Mehta AE et al. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr. Pract. 18(Suppl. 1), 1–78 (2012).
  MedlineGoogle Scholar
• 17 Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl. 2), S1–S45 (2014).
  MedlineGoogle Scholar
• 18 US FDA. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. www.fda.gov/Drugs/DrugSafety/ucm293101.htm
  Google Scholar
• 19 Karalis DG, Victor B, Ahedor L, Liu L. Use of lipid-lowering medications and the likelihood of achieving optimal ldl-cholesterol goals in coronary artery disease patients. Cholesterol 2012, 861924 (2012).
  MedlineGoogle Scholar
• 20 Kauffman AB, Olson KL, Youngblood ML, Zadvorny EB, Delate T, Merenich JA. Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. J. Clin. Lipidol. 4(3), 173–180 (2010).
  MedlineGoogle Scholar
• 21 Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109–2122 (2007). • ILLUMINATE clinical outcomes trial of torcetrapib, terminated due to increased mortality.
  Medline CASGoogle Scholar
• 22 Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255–2267 (2011). •• AIM-HIGH trial that assessed the effect of combination niacin + simvastatin therapy versus simvastatin on HDL-C raising and CVD risk in patients with LDL-C <70 mg/dl.
  MedlineGoogle Scholar
• 23 Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563–1574 (2010). •• Randomized, controlled trial that assessed the effect of combination fibrate + statin therapy versus statin monotherapy on CVD events in patients with Type 2 diabetes mellitus at high CVD risk.
  MedlineGoogle Scholar
• 24 Landray MJ, Haynes R, Hopewell JC et al. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371(3), 203–212 (2014). •• HPS2-THRIVE trial that evaluated the effects of niacin+laropiprant versus statin therapy in high-risk CVD patients.
  Medline CASGoogle Scholar
• 25 Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367(22), 2089–2099 (2012). • Dal-OUTCOMES trial that showed that dalcetrapib had a neutral effect on CVD events.
  Medline CASGoogle Scholar
• 26 Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372(25), 2387–2397 (2015). •• IMPROVE-IT trial that evaluated the clinical outcomes benefit of adding ezetimibe to simvastatin in post acute coronary syndrome patients with high CVD risk with LDL-C ≤125 mg/dl.
  Medline CASGoogle Scholar
• 27 Kamanna VS, Ganji SH, Kashyap ML. Recent advances in niacin and lipid metabolism. Curr. Opin. Lipidol. 24(3), 239–245 (2013).
  Medline CASGoogle Scholar
• 28 Canner PL, Berge KG, Wenger NK et al. 15 year mortality in coronary drug project patients – long-term benefit with niacin. J. Am. Coll. Cardiol. 8(6), 1245–1255 (1986).
  Medline CASGoogle Scholar
• 29 Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231, 360–381 (1975).
  MedlineGoogle Scholar
• 30 Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8(6), 1245–1255 (1986).
  Medline CASGoogle Scholar
• 31 NIH stops clinical trial on combination cholesterol treatment. www.nhlbi.nih.gov/news/press-releases/2011/nih-stops-clinical-trial-on-combination-cholesterol-treatment
  Google Scholar
• 32 Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369(9567), 1090–1098 (2007). • Large, clinical outcomes trial showing eicosapentaenoic acid reduction of major coronary events.
  Medline CASGoogle Scholar
• 33 Kromhout D, Giltay EJ, Geleijnse JM. N-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 363(21), 2015–2026 (2010).
  Medline CASGoogle Scholar
• 34 Rauch B, Schiele R, Schneider S et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122(21), 2152–2159 (2010).
  Medline CASGoogle Scholar
• 35 Bosch J, Gerstein HC, Dagenais GR et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med. 367(4), 309–318 (2012).
  Medline CASGoogle Scholar
• 36 Roncaglioni MC, Tombesi M, Avanzini F et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 368(19), 1800–1808 (2013).
  MedlineGoogle Scholar
• 37 ClinicalTrials Database: NCT01492361. www.clinicaltrials.gov/ct2/show/study/NCT01492361
  Google Scholar
• 38 ClinicalTrials Database: NCT02104817. www.clinicaltrials.gov/ct2/results?term=nct02104817
  Google Scholar
• 39 Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359(13), 1343–1356 (2008). • The SEAS trial compared the effect of combination ezetimibe + simvastatin on a composite of aortic stenosis-related and ischemic cardiac events in patients with aortic stenosis.
  MedlineGoogle Scholar
• 40 Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin + ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784), 2181–2192 (2011). •• Large, randomized controlled trial that showed a reduction of major vascular events with simvastatin plus ezetimibe versus placebo in patients with chronic kidney disease.
  Medline CASGoogle Scholar
• 41 Guyton JR, Slee AE, Anderson T et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J. Am. Coll. Cardiol. 62(17), 1580–1584 (2013).
  Medline CASGoogle Scholar
• 42 Toth PP, Murthy AM, Sidhu MS, Boden WE. Is HPS2-THRIVE the death knell for niacin? J. Clin. Lipidol. 9(3), 343–350 (2015).
  MedlineGoogle Scholar
• 43 Nicholls SJ. Is niacin ineffective? Or did AIM-HIGH miss its target? Cleve. Clin. J. Med. 79(1), 38–43 (2012).
  MedlineGoogle Scholar
• 44 Nicholls SJ. Niacin's effect on cardiovascular risk: have we finally learned our lesson? Cleve. Clin. J. Med. 81(5), 275–277 (2014).
  MedlineGoogle Scholar
• 45 Niaspan, package insert. AbbVie Inc, N Chicago, IL, USA.
  Google Scholar
• 46 Guyton JR, Bays HE. Safety considerations with niacin therapy. Am. J. Cardiol. 99(6A), C22–C31 (2007).
  Google Scholar
• 47 Niaspan, package insert. AbbVie Inc, N Chicago, IL, USA.
  Google Scholar
• 48 Rosenblit PD. Do persons with diabetes benefit from combination statin and fibrate therapy? Curr. Cardiol. Rep. 14(1), 112–124 (2012).
  MedlineGoogle Scholar
• 49 Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med 317(20), 1237–1245 (1987).
  Medline CASGoogle Scholar
• 50 Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N. Engl. J. Med 341(6), 410–418 (1999).
  Medline CASGoogle Scholar
• 51 Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 217(2), 492–498 (2011).
  Medline CASGoogle Scholar
• 52 Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849–1861 (2005).
  Medline CASGoogle Scholar
• 53 Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 45(2), 185–197 (2005).
  Medline CASGoogle Scholar
• 54 Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia. Diabetes Care 25(7), 1198–1202 (2002).
  Medline CASGoogle Scholar
• 55 Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, Type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin. Ther. 26(10), 1599–1607 (2004).
  Medline CASGoogle Scholar
• 56 Farnier M, Ducobu J, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. Am. J. Cardiol. 106(6), 787–792 (2010).
  Medline CASGoogle Scholar
• 57 Farnier M, Steinmetz A, Retterstol K, Csaszar A. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with Type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Clin. Ther. 33(1), 1–12 (2011).
  Medline CASGoogle Scholar
• 58 Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 95(4), 462–468 (2005).
  Medline CASGoogle Scholar
• 59 Koh KK, Quon MJ, Han SH et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J. Am. Coll. Cardiol. 45(10), 1649–1653 (2005).
  Medline CASGoogle Scholar
• 60 Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729), 1875–1884 (2010).
  Medline CASGoogle Scholar
• 61 Sacks FM, Carey VJ, Fruchart JC. combination lipid therapy in Type 2 diabetes. N. Engl. J. Med. 363(7), 692–694 (2010).
  Medline CASGoogle Scholar
• 62 Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J. Cardiovasc. Pharmacol. 57(2), 267–272 (2011).
  Medline CASGoogle Scholar
• 63 Scott R, O'Brien R, Fulcher G et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32(3), 493–498 (2009).
  Medline CASGoogle Scholar
• 64 Chew EY, Ambrosius WT, Davis MD et al. Effects of medical therapies on retinopathy progression in Type 2 diabetes. N. Engl. J. Med. 363(3), 233–244 (2010).
  MedlineGoogle Scholar
• 65 Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370(9600), 1687–1697 (2007).
  Medline CASGoogle Scholar
• 66 Tricor (fenofibrate), prescribing information. AbbVie. www.rxabbvie.com/pdf/tricorpi.pdf
  Google Scholar
• 67 Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am. J. Cardiol. 99(6A), C3–C18 (2007).
  Google Scholar
• 68 Davidson MH, Robinson JG. Safety of aggressive lipid management. J. Am. Coll. Cardiol. 49(17), 1753–1762 (2007).
  Medline CASGoogle Scholar
• 69 Fenoglide^® (fenofibrate), prescribing information. Santarus I. www.accessdata.fda.gov/drugsatfda_docs/label/2012/022118s005lbl.pdf
  Google Scholar
• 70 Lopid^® (gemfibrozil), prescribing information. Pfizer. www.pfizer.com/files/products/uspi_lopid.pdf
  Google Scholar
• 71 Levy P. Bile acid sequestrants as a therapeutic option for glucose lowering in Type 2 diabetes mellitus. Endocr. Pract. 14(5), 644–647 (2008).
  MedlineGoogle Scholar
• 72 Dorr AE, Gundersen K, Schneider JC Jr, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients-effect on serum cholesterol and mortality. J. Chronic. Dis. 31(1), 5–14 (1978).
  Medline CASGoogle Scholar
• 73 The Lipid Research Clinics Investigators. The lipid research clinics coronary primary prevention trial. results of 6 years of post-trial follow-up. Arch. Intern. Med. 152(7), 1399–1410 (1992).
  MedlineGoogle Scholar
• 74 Ye X, Qian C, Liu J, St Peter WL. Lower risk of major cardiovascular events associated with adherence to colesevelam HCI. Pharmacotherapy 33(10), 1062–1070 (2013).
  Medline CASGoogle Scholar
• 75 Toth PP, Nikolic D, Rizz M, Rysz J, Banach M. Use of combination statin and bile acid sequestrant therapy to treat dyslipidemia. In: Combination Therapy in Dyslipidemia. Banach M (Ed.). Springer International Publishing, Cham, Switzerland, 1–10 (2015).
  Google Scholar
• 76 Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323(19), 1289–1298 (1990).
  Medline CASGoogle Scholar
• 77 Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264(23), 3007–3012 (1990).
  Medline CASGoogle Scholar
• 78 WELCHOL^® (colesevelam hydrochloride), prescribing Information. Daiichi Sankyo (2014). http://dsi.com/prescribing-information-portlet/getDocument?product=WC&inline=true
  Google Scholar
• 79 QUESTRAN^® LITE (cholestyramine resin), prescribing information. Par Pharmaceuticals (2013). www.drugs.com/pro/questran.html
  Google Scholar
• 80 Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with Type 2 diabetes. Clin. Ther. 29(1), 74–83 (2007).
  Medline CASGoogle Scholar
• 81 Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with Type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch. Intern. Med. 168(18), 1975–1983 (2008).
  Medline CASGoogle Scholar
• 82 Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31(8), 1479–1484 (2008).
  Medline CASGoogle Scholar
• 83 Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with Type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch. Intern. Med. 168(14), 1531–1540 (2008).
  Medline CASGoogle Scholar
• 84 Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354(9177), 447–455 (1999).
  MedlineGoogle Scholar
• 85 Burr ML, Fehily AM, Gilbert JF et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 2(8666), 757–761 (1989).
  Medline CASGoogle Scholar
• 86 Svensson M, Schmidt EB, Jorgensen KA, Christensen JH. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin. J. Am. Soc. Nephrol. 1(4), 780–786 (2006).
  Medline CASGoogle Scholar
• 87 Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch. Intern. Med. 172(9), 686–694 (2012).
  Medline CASGoogle Scholar
• 88 Matsuzaki M, Yokoyama M, Saito Y et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ. J. 73(7), 1283–1290 (2009).
  Medline CASGoogle Scholar
• 89 Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308(10), 1024–1033 (2012).
  Medline CASGoogle Scholar
• 90 Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106(21), 2747–2757 (2002).
  MedlineGoogle Scholar
• 91 Electronic Medicines Compendium. www.medicines.org.uk/emc/search/?q=omega-3&dt=2
  Google Scholar
• 92 Van de WF, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 29(23), 2909–2945 (2008).
  MedlineGoogle Scholar
• 93 Vascepa, package insert. Amarin Pharma Inc., Bedminster, NJ, USA. www.vascepa.com/full-prescribing-information.pdf
  Google Scholar
• 94 Toth PP, Catapano A, Tomassini JE, Tershakovec AM. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clin. Lipidol. 5(5), 655–684 (2010).
  CASGoogle Scholar
• 95 Holme I, Boman K, Brudi P et al. Observed and predicted reduction of ischemic cardiovascular events in the simvastatin and ezetimibe in aortic stenosis trial. Am. J. Cardiol. 105(12), 1802–1808 (2010). • Substudy of the SEAS trial that assessed the relationship between LDL-C lowering and ischemic risk.
  Medline CASGoogle Scholar
• 96 Gerdts E, Rossebo AB, Pedersen TR et al. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). Am. J. Cardiol. 106(11), 1634–1639 (2010).
  MedlineGoogle Scholar
• 97 Blumenthal RS, Michos ED. The HALTS trial-halting atherosclerosis or halted too early? N. Engl. J. Med. 361(22), 2178–2180 (2009).
  Medline CASGoogle Scholar
• 98 Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N. Engl. J. Med. 358(14), 1504–1507 (2008).
  Medline CASGoogle Scholar
• 99 Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe. N. Engl. J. Med. 358(14), 1507–1508 (2008).
  Medline CASGoogle Scholar
• 100 Kastelein JJ, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N. Engl. J. Med. 361(22), 2180–2183 (2009).
  Medline CASGoogle Scholar
• 101 Toth PP, Maki KC. A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: should ezetimibe move to the ‘Back of the Line’ as a therapy for dyslipidemia? J. Clin. Lipidol. 2(5), 313–317 (2008).
  MedlineGoogle Scholar
• 102 Blazing MA, Guigliano R, Cannon CP et al. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial On-treatment analysis. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_469652.pdf
  Google Scholar
• 103 Murphy SA, Cannon CP, Blazing MA et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J. Am. Coll. Cardiol. 67(4), 353–361 (2016).
  Medline CASGoogle Scholar
• 104 Giugliano RP, Cariou B, Blazing MA et al. Baseline LDL-C and clinical outcomes with additon of ezetimibe to statin in 18, 144 patients post ACS. J. Am. Coll. Cardiol. 65(10 Suppl. 17), A356–A356 (2015).
  Google Scholar
• 105 Bohula EA, Giugliano RP, Cannon CP et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 132(132), 1224–1233 (2015).
  Medline CASGoogle Scholar
• 106 Blazing MA, Guigliano RP, Wiviott SD et al. Muscle-related serious events, drug discontinuations, and complaints in 17,706 subjects randomized to simvastatin or ezetimibe/simvastatin in IMPROVE-IT. Eur. Heart J. 36(Suppl. 1; P6466), 1151–1151 (2015).
  Google Scholar
• 107 Blazing MA, McGuire DK, Cannon CP et al. New-onset diabetes mellitus in the IMPROVE-IT Trial. Presented at: Congress365.escardio.org/European Society of Cardiology Congress 2015. London, UK, 29 August–2 September 2015.
  Google Scholar
• 108 Toth PP, Catapano A, Farnier M et al. Ezetimibe does not increase fasting glucose levels more than statins alone in non-diabetic, hypercholesterolemic patients. J. Am. Coll. Cardiol. 65(10 Suppl. A), 1633–1633 (2015).
  MedlineGoogle Scholar
• 109 Peto R, Emberson J, Landray M et al. Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med. 359(13), 1357–1366 (2008).
  Medline CASGoogle Scholar
• 110 Giugliano RP, Wiviott S, Fuchs CS et al. Prospective evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: a prespecified analysis from the IMPROVE IT trial. Eur. Heart J. 36(Suppl. 1 P1131), 181–181 (2015).
  Google Scholar
• 111 Guigliano RP, Wiviott SD, Blazing MA, Cannon CP, Braunwald E. Safety and efficacy of long-term very low achieved LDL-C in the IMPROVE IT trial. Eur. Heart J. 36(1 Suppl. 68), 2 (2015).
  Google Scholar
• 112 ClinicalTrials Database: NCT01252953. https://clinicaltrials.gov/ct2/show/NCT01252953
  Google Scholar
• 113 ClinicalTrials Database: NCT01687998. https://clinicaltrials.gov/ct2/show/NCT01687998
  Google Scholar
• 114 ClinicalTrials Database: NCT01764633. http://clinicaltrials.gov/show/NCT01764633
  Google Scholar
• 115 ClinicalTrials Database: NCT01663402. http://clinicaltrials.gov/ct2/show/NCT01663402
  Google Scholar
• 116 ClinicalTrials Database: NCT01975376. http://clinicaltrials.gov/ct2/show/NCT01975376
  Google Scholar
• 117 ClinicalTrials Database: NCT01975389. http://clinicaltrials.gov/ct2/show/NCT01975389
  Google Scholar
• 118 Rader DJ, de Goma EM. Future of cholesteryl ester transfer protein inhibitors. Annu. Rev. Med. 65, 385–403 (2014).
  Medline CASGoogle Scholar
• 119 Hovingh GK, Kastelein JJ, van Deventer SJ et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled Phase 2 trial. Lancet 386(9992), 452–460 (2015).
  Medline CASGoogle Scholar
• 120 Merck Provides Update on REVEAL Outcomes Study. www.mercknewsroom.com/news-release/research-and-development-news/merck-provides-update-reveal-outcomes-study
  Google Scholar
• 121 Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease. https://investor.lilly.com/releasedetail.cfm?ReleaseID=936130
  Google Scholar
• 122 beKoren MJ, Lundqvist P, Bolognese M et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled Phase III clinical trial of evolocumab. J. Am. Coll. Cardiol. 63(23), 2531–2540 (2014).
  MedlineGoogle Scholar
• 123 Roth EM, Taskinen MR, Ginsberg HN et al. Monotherapywith the PCSK9 inhibitor alirocumab versus ezetimibe in patients withhypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int. J. Cardiol. 176(1), 55–61 (2014).
  MedlineGoogle Scholar
• 124 Robinson JG, Nedergaard BS, Rogers WJ et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapyon LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 311(18), 1870–1882 (2014).
  MedlineGoogle Scholar
• 125 Kereiakes DJ, Robinson JG, Cannon CP et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally toleratedstatin therapy: The ODYSSEY COMBO I study. Am. Heart J. 169(6), 906–915 (2015).
  Medline CASGoogle Scholar
• 126 Cannon CP, Cariou B, Blom D et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur. Heart J. 36(19), 1186–1194 (2015).
  Medline CASGoogle Scholar
• 127 Sullivan D, Olsson AG, Scott R et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308(23), 2497–2506 (2012).
  Medline CASGoogle Scholar
• 128 Stroes E, Colquhoun D, Sullivan D et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled Phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol. 63(23), 2541–2548 (2014).
  Medline CASGoogle Scholar
• 129 Moriarty PM, Jacobson TA, Bruckert E et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized Phase 3 trial. J. Clin. Lipidol. 8(6), 554–561 (2014).
  MedlineGoogle Scholar
• 130 Raal FJ, Stein EA, Dufour R et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385(9965), 331–340 (2015).
  Medline CASGoogle Scholar
• 131 Kastelein JJ, Ginsberg HN, Langslet G et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J. 36(43), 2996–3003 (2015).
  Medline CASGoogle Scholar
• 132 Raal FJ, Honarpour N, Blom DJ et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385(9965), 341–350 (2015).
  Medline CASGoogle Scholar
• 133 Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372(16), 1500–1509 (2015).
  Medline CASGoogle Scholar
• 134 Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372(16), 1489–1499 (2015).
  Medline CASGoogle Scholar
• 135 Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J. Am. Coll. Cardiol. 65(24), 2638–2651 (2015).
  Medline CASGoogle Scholar
• 136 TOC. Repatha, package insert. Amgen Inc. http://pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdf
  Google Scholar
• 137 Praluent, package insert. Sanofi-Aventis BN. www.regeneron.com/Praluent/Praluent-fpi.pdf
  Google Scholar
• 138 European Commission approves amgen's new cholesterol-lowering medication Repatha™ (Evolocumab), the first PCSK 9 inhibitor to be approved in the world, for treatment of high cholesterol. www.multivu.com/players/English/7414052-amgen-repatha/
  Google Scholar
• 139 Regeneron and Sanofi announce approval of Praluent^® (alirocumab) for the treatment of hypercholesterolemia in the European Union. http://newsroom.regeneron.com/releasedetail.cfm?ReleaseID=933278
  Google Scholar
• 140 McGowan MP, Tardif J-C, Ceska R et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE 7(11), e49006 (2012).
  Medline CASGoogle Scholar
• 141 Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375(9719), 998–1006 (2010).
  Medline CASGoogle Scholar
• 142 Stein EA, Dufour R, Gagne C et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126(19), 2283–2292 (2012).
  Medline CASGoogle Scholar
• 143 Visser ME, Wagener G, Baker BF et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur. Heart J. 33(9), 1142–1149 (2012).
  Medline CASGoogle Scholar
• 144 US FDA. FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337195.htm
  Google Scholar
• 145 Cuchel M, Meagher EA, du Toit TH et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, Phase 3 study. Lancet 381(9860), 40–46 (2013).
  Medline CASGoogle Scholar
• 146 US FDA. FDA approves new orphan drug for rare cholesterol disorder. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm
  Google Scholar
• 147 EMA. Lojuxta, prescribing information. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002578/WC500148549.pdf
  Google Scholar
• 148 Desai NR, Sabatine MS. PCSK9 inhibition in patients with hypercholesterolemia. Trends Cardiovasc. Med. 25(7), 567–574 (2015).
  Medline CASGoogle Scholar
• 149 Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjaerg-Hansen A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J. Am. Coll. Cardiol. 60(20), 2041–2048 (2012).
  Medline CASGoogle Scholar
• 150 Ridker PM, Pare G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18,245 initially healthy women from the Women's Genome Health Study. Circ. Cardiovasc. Genet. 2(1), 26–33 (2009).
  Medline CASGoogle Scholar
• 151 Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet 384(9943), 618–625 (2014).
  Medline CASGoogle Scholar
• 152 Rohatgi A, Khera A, Berry JD et al. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371(25), 2383–2393 (2014).
  Medline CASGoogle Scholar
• 153 Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354(12), 1264–1272 (2006).
  Medline CASGoogle Scholar
• 154 Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J. Am. Coll. Cardiol. 65(15), 1552–1561 (2015). •• Genetic study showing loss of function mutations in NPC1L1 and HMGCoA reductase have similar magnitudes of CHD reduction related to the magnitude of LDL-C lowering and are additive.
  Medline CASGoogle Scholar
• 155 Stitziel NO, Won HH, Morrison AC et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 371(22), 2072–2082 (2014).
  MedlineGoogle Scholar
• 156 Goff DC Jr, Lloyd-Jones DM, Bennett G et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl. 2), S49–S73 (2014).
  MedlineGoogle Scholar
• 157 Jacobson TA, Ito MK, Maki KC et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1 – full report. J. Clin. Lipidol. 9(2), 129–169 (2015).
  MedlineGoogle Scholar